Skip to main content
Premium Trial:

Request an Annual Quote

Divining the Future

There's a thread at SeqAnswers that asks whether researchers will stop using the Roche 454 as the Illumina chemistry improves. While the answers vary, many contributors to the thread note that Roche "won't stand still," as Maubp puts it.

Mike the Mad Biologist gives his take on his own blog, where he says that he has already stopped using 454 for his microbial genomics work. "Compared to Illumina assemblies that use 5 kb jumps (and are thus able to span most of the repetitive regions), 454 isn't even in the same league," Mike says. "Combined with the much lower cost of generating Illumina sequence data, 454 is really out of the bacterial genome game." However, Mike adds that "I could see 454 being useful if you need long reads and not that many of them."

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.